In short
A Phase III clinical trial is underway to investigate the effects of N-Acetyl-L-Leucine on patients with Niemann-Pick disease type C (NPC). This randomized, placebo-controlled, double-blind, crossover study aims to evaluate the drug's efficacy, safety, and tolerability in treating NPC symptoms, particularly focusing on ataxia (loss of coordination) and overall quality of life for patients aged 4 years and older.
At a glance
- Study Type
- Phase III, randomized, placebo-controlled, double-blind, crossover study
- Drug Name
- N-Acetyl-L-Leucine (IB1001)
- Condition
- Niemann-Pick disease type C (NPC)
- Primary Objective
- Evaluate efficacy based on the Scale for the Assessment and Rating of Ataxia (SARA)
- Secondary Objectives
- Assess clinical efficacy on symptoms, functioning, and quality of life; Evaluate safety and tolerability
- Eligibility
- Age ≥4 years, confirmed NPC diagnosis, specific SARA score range, weight ≥15 kg
- Dosage
- 4 g/day for patients ≥13 years; weight-tiered doses for patients 4-12 years
- Primary Endpoint
- Scale for the Assessment and Rating of Ataxia (SARA)
- Secondary Endpoints
- SCAFI, Quality of Life assessments, mDRS, CGI-I
What is L-Acetylleucine?
L-Acetylleucine, also known as N-Acetyl-L-Leucine, is a medication currently being studied for the treatment of a rare genetic disorder called Niemann-Pick Disease Type C (NPC). This drug is considered a "small molecule," which means it's a low molecular weight compound that can easily enter cells to perform its function.
Niemann-Pick Disease Type C
Niemann-Pick Disease Type C is a rare genetic disorder that affects the body's ability to process and transport fats (lipids) within cells. This leads to an accumulation of lipids in various organs, particularly the brain, liver, and spleen. NPC is classified as a congenital familial and genetic disorder, meaning it's inherited and present from birth.
Ongoing Research
A Phase III clinical trial is currently underway to evaluate the effectiveness and safety of L-Acetylleucine in treating NPC. This is an advanced stage of research, indicating that the drug has shown promise in earlier studies and is now being tested on a larger group of patients.
How L-Acetylleucine Works
The main goal of using L-Acetylleucine in NPC patients is to improve their ataxia, which refers to problems with balance, coordination, and speech. Researchers are using a special scale called the Scale for the Assessment and Rating of Ataxia (SARA) to measure how well the drug works.
Eligibility for the Study
To participate in the study, patients must meet certain criteria:
- Be at least 4 years old
- Have a confirmed diagnosis of NPC
- Have specific scores on tests that measure ataxia and hand function
- Weigh at least 15 kg (about 33 pounds)
Some factors that might prevent a person from participating include:
- Known allergies to the drug or its ingredients
- Participation in other clinical trials
- Certain physical or psychiatric conditions that might interfere with the study
- Diagnosed arthritis or other musculoskeletal disorders that significantly affect mobility
Study Design
The study is designed as a randomized, placebo-controlled, double-blind, crossover study. This means:
- Participants are randomly assigned to receive either L-Acetylleucine or a placebo (a substance with no active ingredients).
- Neither the patients nor the researchers know who is receiving the real drug or the placebo during the study.
- After a period of time, the groups switch, so everyone gets a chance to receive the real drug.
This design helps ensure that the results are as accurate and unbiased as possible.
Potential Benefits
If successful, L-Acetylleucine could potentially improve several aspects of life for NPC patients:
- Better control of ataxia symptoms
- Improved overall functioning
- Enhanced quality of life
Researchers are using various tests to measure these potential improvements, including the Spinocerebellar Ataxia Functional Index (SCAFI) and quality of life questionnaires.
Safety Considerations
The study is also closely monitoring the safety and tolerability of L-Acetylleucine. The dosage being tested is 4 g/day for patients 13 years and older, with weight-adjusted doses for younger patients (ages 4 to 12). As with any medication, it's important to be aware of potential side effects, which will be carefully documented throughout the study.